Oxaliplatin Market Scope
Oxaliplatin is a platinum-based drug used in the treatment of stage III colon cancer, who have undergone complete resection of the primary tumor and also for the treatment of advanced colorectal cancer. This medicine canít take on high allergic reactions, Neuropathy, Pulmonary Toxicity, Hepatotoxicity, and Pregnancy. It is commonly known as a trading name as Eloxatin.
The market study is being classified by Type (Mannitol, Glucose Solution, Lactose Solution and Others), by Application (Colorectal Cancer (XELOX), Pancreatic Cancer, Gastroesophageal Cancer, Testicular Cancer, Cancer of Unknown Primary Origin and Ovarian Cancer) and major geographies with country level break-up.
The global Oxaliplatin market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability. Research Analyst at AMA predicts that China Players will contribute to the maximum growth of Global Oxaliplatin market throughout the predicted period.
Sanofi (France), Yakult honsha (Japan), Dr. Reddy's Laboratories (India), Sun Pharmaceutical (India), Teva Pharmaceutical Industries (Israel), Fresenius Kabi (Germany), Hospira (United States), Mylan (United States), Jiangsu Hengrui Medicine (China) and Nanjing Pharmaceutical Factory (China) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Hisun Pharmaceutical (United States), Chia Tai-Tianqing Pharmaceutical Holdings Co., Ltd (China), Jiangsu Aosaikang Pharmaceutical (China) and Qilu Pharmaceutical (China).
AdvanceMarketAnalytics has segmented the market of Global Oxaliplatin market by Type, Application and Region.
On the basis of geography, the market of Oxaliplatin has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In Nov 2018, Merck announced the approval of the KEYTRUDA drug from the United States Food and Drug Administration. KEYTRUDA is defined for the treatment of adult and pediatric patients. It is used in colorectal cancer that has progressed the treatments with oxaliplatin.
- Increasing Number of Research and Development Activities
- Technology Advancement in Manufacturing Equipment
- Increase Number of Cancer Patients across the Globe, But Majorly in the United States Region
- Increasing Number of Drug Manufacturing Companies
- Rise in Distribution Channels among Emerging Economies
- Stringent Government Regulations
- Rising Concern towards High Number of Side Effects
Key Target AudienceVenture Capitalists and Private Equity Firms, New Entrants/Investors, Analysts and Strategic Business Planners, Oxaliplatin Manufacturers, Suppliers and Distributors, Raw Material Suppliers, Government Regulatory and Research Organizations and End-Use Industries
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase